Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 71% of modeled bridge. Strengths: Occupancy Rate. Risk-adjusted uplift: $8.7M (vs $12.3M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $4.7M | $4.7M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $4.5M | $128K | $4.6M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $716K | $2.1M | $2.8M | $9.0M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $149K | $149K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 42.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $1.2M | $2.3M | $3.5M | $4.7M | $4.7M | $4.7M | $4.7M |
| Denial Rate Reduction | $0 | $1.2M | $2.3M | $3.5M | $4.6M | $4.6M | $4.6M | $4.6M |
| A/R Days Reduction | $0 | $947K | $1.9M | $2.8M | $2.8M | $2.8M | $2.8M | $2.8M |
| Clean Claim Rate | $0 | $75K | $149K | $149K | $149K | $149K | $149K | $149K |
| Cumulative | $0 | $3.3M | $6.7M | $10.0M | $12.3M | $12.3M | $12.3M | $12.3M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $12.3M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | Loss | Loss |
| 9.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 10.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 11.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 12.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 0% before the 6.5x covenant trips. RCM uplift reduces leverage from 99.0x to 99.0x, adding 0.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $-15.2M | — | $-15.2M | -6.5% |
| Year 1 | $-15.6M | +$8.2M | $-7.4M | -3.2% |
| Year 2 | $-16.1M | +$12.3M | $-3.8M | -1.6% |
| Year 3 | $-16.6M | +$12.3M | $-4.3M | -1.8% |
| Year 4 | $-17.1M | +$12.3M | $-4.8M | -2.1% |
| Year 5 | $-17.6M | +$12.3M | $-5.3M | -2.3% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $2.3M | $3.5M | $4.7M | $5.6M |
| Denial Rate Reductio | $2.3M | $3.5M | $4.6M | $5.5M |
| A/R Days Reduction | $1.4M | $2.1M | $2.8M | $3.4M |
| Clean Claim Rate | $75K | $112K | $149K | $179K |
| Total | $6.1M | $9.2M | $12.3M | $14.7M |
Peer Context — Where This Hospital Sits
Key metrics vs 97 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | -6.5% | -27.5% | -17.0% | -9.2% | P83 |
| Net-to-Gross | 25.5% | 26.4% | 32.8% | 42.0% | P20 |
| Occupancy | 69.1% | 51.2% | 68.6% | 81.8% | P52 |
| Rev/Bed | $1.4M | $886K | $1.4M | $2.0M | P51 |
| Exp/Bed | $1.5M | $811K | $1.5M | $2.1M | P49 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.